Haas Jason has filed 16 insider transactions across 2 companies since March 2024.
Most recent transaction: a grant/award of 5783 shares of LIGAND PHARMACEUTICALS INC ($LGND) on June 06, 2025.
Activity breakdown: 3 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 6, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Haas Jason | Director | A | Non-Qualified Stock Option (right to buy) | 5783 | $0.00 | 5,783.0000 | 18,290,000 | 9999.99% | 0.03% |
| June 6, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Haas Jason | Director | A | Common Stock | 1209 | $0.00 | 6,606.0000 | 18,290,000 | 22.40% | 0.01% |
| Nov. 18, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | S | Common Stock | 137803 | $0.21 | 0.0000 | 39,335,772 | 100.00% | 0.35% |
| Oct. 31, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | F | Common Stock | 5624 | $2.09 | 137,803.0000 | 39,335,772 | 3.92% | 0.01% |
| Oct. 31, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | M | Restricted Stock Units | 18875 | $0.00 | 0.0000 | 39,335,772 | 100.00% | 0.05% |
| Oct. 31, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | M | Common Stock | 18875 | $0.00 | 143,427.0000 | 39,335,772 | 15.15% | 0.05% |
| Sept. 10, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | P | Common Stock | 35363 | $1.55 | 59,915.0000 | 28,325,779 | 144.03% | 0.12% |
| Sept. 11, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | P | Common Stock | 19293 | $1.58 | 79,208.0000 | 28,325,779 | 32.20% | 0.07% |
| Sept. 12, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | P | Common Stock | 45344 | $1.68 | 124,552.0000 | 28,325,779 | 57.25% | 0.16% |
| June 14, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Haas Jason | Director | A | Non-Qualified Stock Option (right to buy) | 5444 | $0.00 | 5,444.0000 | 17,757,000 | 9999.99% | 0.03% |
| June 14, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Haas Jason | Director | A | Common Stock | 1252 | $0.00 | 5,397.0000 | 17,757,000 | 30.21% | 0.01% |
| March 31, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 15,951.0000 | 28,325,779 | 14.34% | 0.01% |
| March 31, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 4,000.0000 | 28,325,779 | 33.33% | 0.01% |
| April 1, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | F | Common Stock | 4732 | $5.12 | 24,552.0000 | 28,325,779 | 16.16% | 0.02% |
| March 31, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | M | Common Stock | 13333 | $0.00 | 29,284.0000 | 28,325,779 | 83.59% | 0.05% |
| March 31, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Haas Jason | Chief Financial Officer | M | Restricted Stock Units | 13333 | $0.00 | 26,667.0000 | 28,325,779 | 33.33% | 0.05% |